![logo](/logos/EGTX.ST.webp)
Egetis Therapeutics AB (publ)
SSE:EGTX.ST
6.07 (SEK) • At close February 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Egetis Therapeutics AB (publ) |
Symbool | EGTX.ST |
Munteenheid | SEK |
Prijs | 6.07 |
Beurswaarde | 1,775,905,970 |
Dividendpercentage | 0% |
52-weken bereik | 3.8 - 9.2 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Nicklas Westerholm |
Website | https://www.egetis.com |
An error occurred while fetching data.
Over Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning,
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (SEK)
Cijfers zijn in miljoenen (SEK)